EP0994869A1 - Maleate de 5-(2-ethyl-2h-tetrazole-5-yl)-1-methyle-1,2,3,6-tetrahydropyridine - Google Patents

Maleate de 5-(2-ethyl-2h-tetrazole-5-yl)-1-methyle-1,2,3,6-tetrahydropyridine

Info

Publication number
EP0994869A1
EP0994869A1 EP98930655A EP98930655A EP0994869A1 EP 0994869 A1 EP0994869 A1 EP 0994869A1 EP 98930655 A EP98930655 A EP 98930655A EP 98930655 A EP98930655 A EP 98930655A EP 0994869 A1 EP0994869 A1 EP 0994869A1
Authority
EP
European Patent Office
Prior art keywords
acid addition
addition salt
ethyl
maleic acid
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98930655A
Other languages
German (de)
English (en)
Inventor
Michael Bech Sommer
Ole Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of EP0994869A1 publication Critical patent/EP0994869A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a maleic acid addition salt of 5-(2-ethyl-2/-/-tetrazol- 5-yl)-1 -methyl-1 ,2,3,6-tetrahydropyridine, pharmaceutical compositions containing the acid addition salt and the use thereof for the treatment of diseases or disorders caused by a malfunction of the cholinergic or muscarinic system.
  • US patent No. 4,866,077 discloses a series of piperidine and tetrahydropyridine compounds substituted in position 5 with a 1 ,2,3-triazoie or a tetrazole group. These compounds have high affinity to central AcCh receptors, including muscarinic M1 receptors, and are considered useful for the treatment of disorders involving malfunction of the cholinergic system, e.g. Alzheimer's disease, senile dementia, and impaired learning or memory function.
  • 5-(2-ethyl-2H-tetrazol-5-yl)-1 -methyl-1 , 2,3,6- tetrahydropyridine may be useful for the treatment of traumatic brain injury (TBI) and psychosis or other schizophreniform diseases (WO97/17074 and co-pending PCT application claiming priority from DK 620/97).
  • TBI may be caused by various physical and neurological conditions or diseases such as conditions associated with trauma to the brain or spinal cord e.g. caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or embolism, neurological problems caused by AIDS, cerebral hemorrhage, encephaiomyelitis, hydrocephalus, postoperative events, cerebral infections, concussions, or elevated intracranial pressure.
  • conditions associated with trauma to the brain or spinal cord e.g. caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or embolism, neurological problems caused by AIDS, cerebral hemorrhage, encephaiomyelitis, hydrocephalus, postoperative events, cerebral infections, concussions, or elevated intracranial pressure.
  • Psychosis means to include all forms of psychoses such as organic psychoses, drug induced psychoses, Alzheimer related psychoses, and psychoses or related conditions associated with other mental disorders, such as paranoid personality disorder, ect.
  • schizophrenia and schizophreniform diseases include all types of such disorders, e.g. catatonic, disorganised, paranoid, undifferential and residual schizo- phrenia, and all conditions associated with such diseases, including the positive and negative symptoms thereof.
  • the 5-(2-ethyl-2/-/-tetrazol-5-yl)-1 -methyl-1 ,2,3,6-tetrahydropyridine free base is a liquid and as such not suitable for the production of solid pharmaceu- tical preparations, such as tablets or capsules.
  • oral administration a solid entity is the preferred and most convenient method for the administration of a pharmaceutical, a solid form of 5-(2-ethyl-2H-tetrazol-5-yl)-1 -methyl-1 , 2,3,6- tetrahydropyridine, suitably a pharmaceutically acceptable salt thereof, which can be mixed with various adjuvants or diluents and formed into tablets or filled in cap- sules, is highly desirable.
  • oxalic acid addition salt of 5-(2-ethyl-2/-/-tetrazol-5-yl)-1 -methyl-1 ,2,3,6-tetra- hydropyridine is specifically disclosed in US patent No. 4,866,077.
  • oxalic acid addition salts may be particularly useful for crystallization and purification purposes, they are not suitable for the preparation of pharmaceuticals due to the toxicity of oxalic acid.
  • a pharmaceutically acceptable salt of 5-(2-ethyl-2H-tetrazol-5-yl)-1 -methyl-1 ,2,3,6- tetrahydropyridine, the tartrate, has been described in Moltzen et al., J. Med. C ?e .1994, 37, 4085-4099. Unfortunately, the tartrate is difficult to precipitate and recrystallize in large scale productions. Accordingly, the tartrate salt is not suitable for commercial production of solid pharmaceutical preparations.
  • the maleic acid addition salt of 5-(2-ethyl-2H- tetrazol-5-yl)-1 -methyl-1 ,2,3,6-tetrahydropyridine and pharmaceutical compositions comprising said acid addition salt have been provided.
  • the maleic acid addition salt according to the invention may be obtained by treatment of 5-(2-ethyl-2H-tetrazol-5-yl)-1 -methyl-1 ,2,3,6-tetrahydropyridine or a salt derivative thereof with maleic acid in an inert solvent, followed by precipitation, isolation and optionally recrystallization by known methods and if desired followed by micronisation of the crystalline product by wet or dry milling or another convenient process, or preparation of particles from a solvent-emulsification process. Precipitation of the maleate salt is carried out in an inert aprotic solvent, preferably tetrahydrofuran (THF).
  • THF tetrahydrofuran
  • the maleate acid addition salt of the invention may be administered in any suitable way e.g. orally or parenterally, and the compounds may be presented in any suitable form for such administration, e.g. in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection.
  • the maleate of the invention is administered in the form of a solid pharmaceutical entity, suitably as a tablet or a capsule.
  • Tablets may thus be prepared by mixing the active ingredients with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a convenient tabletting machine.
  • adjuvants or diluents comprise: corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive colourings, aroma, preservatives, etc. may also be used provided that they are compatible with the active ingredients.
  • the compound of the invention is most conveniently administered orally in unit dos- age forms such as tablets or capsules, containing the active ingredient in an amount from about 10 ⁇ g/day/kg to 15 mg/day/kg body weight, preferably 25 ⁇ g/day/kg to 10 mg/day/kg and most preferred 4-5- mg/kg/day body weight.
  • a suitable daily dose is 500 ⁇ g to 1000 mg/day, preferably 1.0 to 500 mg/day and most preferred 300-400 mg/day.
  • the maleate acid addition salt according to the invention is readily soluble in water, alcohol and other polar solvents and may, if desired, be used for the preparation of solutions for injection.
  • Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the vehicle, preferably sterile water, adjusting the solution to the desired volume, sterilization of the solution, and filling in suitable am- poules or vials.
  • Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, ect.
  • the 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1 ,2,3,6-tetrahydropyridine, oxalate starting material can be prepared as described in US patent No. 4,866,077.
  • the precipitate was isolated on a nutche filter, and washed with tetrahydrofuran (2 x 2 L).
  • the wet filtercake was recrystailized once from tetrahydrofuran (13 L).
  • the recrystallized material was isolated on a nutche filter, washed with tetrahydrofuran (5 L), and finally dried in vacuo at 65 °C overnight. Yield 5.0. kg (83%) mono- maleate. M.p. 116 °C.
  • Recrvstallisation A reactor was charged with 5-(2-ethyl-2H-tetrazoi-5-yl)-1-methyl- 1 ,2,3,6-tetrahydropyridine, maleate, and tetrahydrofuran. The solution was heated to reflux and then allowed to crystallize (1) . The product was isolated, washed several times with THF, and dried in vacuo.
  • the solution may be seeded with 5-(2-ethyl-2H-tetrazol-5-yl)-1- methyl-1 ,2,3,6-tetrahydropyridine, maleate from a previous batch.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un sel d'addition d'acide maléique de 5-(2-éthyl-2H-tétrazol-5-yl)-1-méthyl-1,2,3,6-tétrahydropyridine, des compositions pharmaceutiques contenant ledit sel d'addition d'acide ainsi que leur utilisation dans le traitement de troubles provoqués par un dysfonctionnement du système de l'acétylcholine (AcCh) ou du système muscarinique.
EP98930655A 1997-07-01 1998-07-01 Maleate de 5-(2-ethyl-2h-tetrazole-5-yl)-1-methyle-1,2,3,6-tetrahydropyridine Withdrawn EP0994869A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK78197 1997-07-01
DK78197 1997-07-01
PCT/DK1998/000294 WO1999001448A1 (fr) 1997-07-01 1998-07-01 Maleate de 5-(2-ethyl-2h-tetrazole-5-yl)-1-methyle-1,2,3,6-tetrahydropyridine

Publications (1)

Publication Number Publication Date
EP0994869A1 true EP0994869A1 (fr) 2000-04-26

Family

ID=8097489

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98930655A Withdrawn EP0994869A1 (fr) 1997-07-01 1998-07-01 Maleate de 5-(2-ethyl-2h-tetrazole-5-yl)-1-methyle-1,2,3,6-tetrahydropyridine

Country Status (25)

Country Link
EP (1) EP0994869A1 (fr)
JP (1) JP2002507215A (fr)
KR (1) KR20010014297A (fr)
CN (1) CN1261361A (fr)
AR (1) AR013096A1 (fr)
AU (1) AU735751B2 (fr)
BG (1) BG103933A (fr)
BR (1) BR9810331A (fr)
CA (1) CA2293324A1 (fr)
CO (1) CO4940483A1 (fr)
EA (1) EA200000081A1 (fr)
HU (1) HUP0002876A2 (fr)
IL (1) IL133093A0 (fr)
IS (1) IS5278A (fr)
JO (1) JO2031B1 (fr)
MA (1) MA25138A1 (fr)
NO (1) NO996580L (fr)
PE (1) PE116099A1 (fr)
PL (1) PL337184A1 (fr)
SK (1) SK187399A3 (fr)
TN (1) TNSN98120A1 (fr)
TR (1) TR199903283T2 (fr)
UY (2) UY25069A1 (fr)
WO (1) WO1999001448A1 (fr)
ZA (1) ZA985498B (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
TR199800801T2 (xx) * 1995-11-06 1998-08-21 H. Lund-Beck A/S Travmatik beyin yaralanmalar�n�n tedavisi.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9901448A1 *

Also Published As

Publication number Publication date
PE116099A1 (es) 1999-11-23
JP2002507215A (ja) 2002-03-05
CO4940483A1 (es) 2000-07-24
BG103933A (en) 2000-07-31
CA2293324A1 (fr) 1999-01-14
IS5278A (is) 1999-11-30
AR013096A1 (es) 2000-12-13
SK187399A3 (en) 2000-06-12
NO996580D0 (no) 1999-12-30
HUP0002876A2 (hu) 2001-06-28
CN1261361A (zh) 2000-07-26
TR199903283T2 (xx) 2000-06-21
AU735751B2 (en) 2001-07-12
AU8102098A (en) 1999-01-25
NO996580L (no) 1999-12-30
JO2031B1 (en) 1999-05-15
BR9810331A (pt) 2000-09-05
MA25138A1 (fr) 2001-04-02
PL337184A1 (en) 2000-08-14
UY25069A1 (es) 1998-12-21
WO1999001448A1 (fr) 1999-01-14
UY25177A1 (es) 2000-12-29
EA200000081A1 (ru) 2000-08-28
ZA985498B (en) 1999-01-20
IL133093A0 (en) 2001-03-19
KR20010014297A (ko) 2001-02-26
TNSN98120A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
CN101031548B (zh) N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
ES2229342T3 (es) Sales de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona(=ziprasidona),su preparacion y uso como antagonista de dopamina d2.
DE69111816T2 (de) Indolederivate und ihre verwendung als serotonin-antagoniste.
EP0610793A1 (fr) Dérivés de morpholine tétracycliques et leur utilisation comme analgésiques
JPH054983A (ja) イソキノリノン誘導体、その製造方法およびその誘導体を有効成分として含有する５−ｈｔ３ レセプター拮抗剤
JPH09500875A (ja) タキキニン拮抗薬としての４−フェニル−４−フェニルプロピル（エチル）−ピペリジン
WO2005085199A1 (fr) Nouvelles formes polymorphes d'etoricoxib
WO1992017473A1 (fr) Monohydrate d'hydrochlorure de tiagabine cristalline, sa preparation et son utilisation
CH695216A5 (de) Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
MXPA03005888A (es) Base libre de amlodipina.
WO2004092137A1 (fr) Nouvelles formes cristallines de chlorhydrate de donepezil
JPH09510222A (ja) ２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピン化合物の酸付加塩
CA2164296C (fr) Chimie heterocyclique
AU735751B2 (en) 5-(2-ethyl-2H-tetrazol-5-Y1)-1-methyl-1,2,3,6-tetrahydro pyridine maleate
MXPA03005884A (es) Hemimaleato de amlodipina.
EP1858847A1 (fr) Chlorhydrate de donepezil de formule i stable et son procede de preparation et d'utilisation dans des compositions pharmaceutiques
US7335380B2 (en) Amlodipine free base
DE69515498T2 (de) Naphthyridinderivate
MXPA99011450A (en) 5-(2-ethyl-2h
EP0523013B1 (fr) Utilisation des dérivés de l'acide benzimidazoline-2-oxo-1-carboxylique dans le traitement des maladies mentales organiques
CZ477899A3 (cs) 5-(2-ethyI-2H-tetrazol-5-yl)-l-methyl-l,2,3,6- tetrahydropyridinmaleátová adiční sůl
KR20000075907A (ko) (ｅ)-4,6-디클로로-3-(2-옥소-1-페닐피롤리딘-3-일리덴 메틸)-1ｈ-인돌-2-카르복실산의 결정질 수화 나트륨염
EP1355632B1 (fr) Base libre d'amlodipine
EP0322034A2 (fr) Tétrahydropyridylméthyl oxadiazoles
JPH05310735A (ja) 置換３−アミノキヌクリジンｐ物質拮抗剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000201;LT PAYMENT 20000201;LV PAYMENT 20000201;MK PAYMENT 20000201;RO PAYMENT 20000201;SI PAYMENT 20000201

RTI1 Title (correction)

Free format text: 5-(2-ETHYL-2H-TETRAZOL-5-Y1)-1-METHYL-1,2,3,6-TETRAHYDROPYRIDINE MALEATE

17Q First examination report despatched

Effective date: 20001010

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010421